Welcome to our dedicated page for ReShape Lifesciences SEC filings (Ticker: RSLS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RSLS SEC filings archive documents the regulatory history of ReShape Lifesciences Inc. prior to and through its transformation into Vyome Holdings, Inc. These filings, made with the U.S. Securities and Exchange Commission, provide detailed information on the company e2 80 99s weight loss and metabolic health device business, its major strategic transactions, and the subsequent name and ticker change to HIND on The Nasdaq Capital Market.
Key filings include multiple Form 8-K current reports describing material events. Among them are disclosures of the Agreement and Plan of Merger with Vyome Therapeutics, Inc., the closing of the merger on August 15, 2025, and the resulting change of the registrant e2 80 99s name to Vyome Holdings, Inc. They also describe the 1-for-4 reverse stock split of the company e2 80 99s common stock and the continuation of Nasdaq listing under the new trading symbol HIND. Other 8-K filings detail shareholder meeting results, including approvals of share issuances, the asset sale, charter amendments, and reverse split authorization.
The filings further outline the Asset Purchase Agreement with Ninjour Health International Limited, an affiliate of Biorad Medisys Pvt. Ltd., under which ReShape Lifesciences sold substantially all of its assets (excluding cash) and Biorad assumed substantially all of its liabilities. Disclosures specify that the Lap-Band ae System, Obalon ae Gastric Balloon System, and the DBSN ae system were among the assets transferred. Additional 8-K items address financing arrangements, such as an equity distribution agreement for at-the-market offerings, and changes in the company e2 80 99s independent registered public accounting firm.
After the merger, subsequent 8-K and 8-K/A filings under the Vyome Holdings, Inc. name (trading as HIND) provide Vyome e2 80 99s financial statements, management e2 80 99s discussion and analysis, and unaudited pro forma condensed combined financial statements giving effect to the merger. Amendments such as 8-K/A filings correct and update pro forma calculations, ensuring that the combined company e2 80 99s financial presentation is accurate for incorporation into existing shelf registration statements.
On Stock Titan, users can access these RSLS-related SEC filings in one place, with real-time updates pulled from EDGAR. AI-powered summaries help explain the significance of complex documents like 8-K merger reports, reverse stock split disclosures, and pro forma financial statements. Investors can also review historical ownership and governance changes, as reflected in board and executive transitions reported in the filings, and trace how the former ReShape Lifesciences entity evolved into Vyome Holdings, Inc. under the HIND ticker.
ReShape Lifesciences (RSLS) is asking its shareholders to approve two transformative transactions: (i) a reverse-merger with privately held Vyome Therapeutics and (ii) the sale of substantially all ReShape operating assets to U.K.-based Biorad for $2.25 million cash plus working-capital adjustments. At closing, Merger Sub will combine with Vyome, Vyome will survive as a wholly-owned subsidiary, and the parent will be renamed Vyome Holdings, Inc. The exchange ratio will be set 10 days before the special meeting so that Vyome security-holders own 88.9-92.31% of the fully-diluted shares, leaving current ReShape holders with 7.69-11.1%, subject to a net-cash true-up against a $5 million target.
ReShape’s balance-sheet assets (other than cash) and virtually all liabilities will transfer to Biorad, simplifying the combined company’s capital structure and sharpening its focus on Vyome’s immuno-inflammatory pipeline. ReShape has already loaned Vyome $400,000 at 8% interest to cover merger expenses; the note will be forgiven at closing but becomes senior secured if the deal fails due to financing issues. To retain a Nasdaq listing, the combined company must satisfy initial listing standards, including a $4.00 minimum share price; if approved, the ticker is expected to change to “HIND.”
ReShape will hold a virtual special meeting where shareholders will vote on (1) issuing new shares for the merger and (2) approving the asset sale. Vyome has already secured written consent from >50% of its voting shares, so no Vyome meeting is required. The boards of both companies unanimously recommend voting “FOR” all proposals, but completion remains contingent on shareholder approval and Nasdaq acceptance.
ReShape Lifesciences (Nasdaq: RSLS) filed an 8-K (Item 8.01 – Other Events) disclosing its current status with Nasdaq listing requirements. On May 28 2025 the company received a delisting notice for failing to meet the Nasdaq Capital Market’s minimum $2.5 million stockholders’ equity requirement; equity stood at only $1.2 million as of March 31 2025.
Since the notice, ReShape raised additional capital in two transactions: (1) 593,000 common shares sold between June 3–6 2025 via its at-the-market program for $3.64 million gross proceeds, and (2) an offering completed June 9 2025 of 1,054,604 shares for $2.64 million gross proceeds. Pro forma for these raises, management states that stockholders’ equity now exceeds $2.5 million.
The company has requested a hearing before a Nasdaq Hearings Panel, which automatically stays any suspension or delisting action until the Panel issues a decision and any permitted extension period expires. Management cautions that merely surpassing the equity threshold does not guarantee continued listing; the final outcome depends on the Panel’s review.
Investors should monitor the Panel’s ruling and ReShape’s ability to sustain equity levels, as delisting would shift trading to an over-the-counter venue and could impact liquidity and valuation.